CD274 and intrahepatic cholangiocarcinoma: For example, various small-molecule inhibitors targeting RNA N6-methyladenosine modification have been demonstrated to reduce the progression of intrahepatic cholangiocarcinoma [51] and synergistically inhibit colon cancer with anti-PDL1 blockade [52] in mouse models.